- Company
- Credit ratings for Samsung Biologics·JW Holdings↑
- by Kim, Jin-Gu Jul 10, 2025 06:08am
- Major pharmaceutical and biotech companies (biopharma companies) are facing varying differing credit ratings and outlooks. While Samsung Biologics and JW Holdings received upward credit ratings, Handok was downgraded. Dong-A ST's credit rating outlook shifted from 'stable' to 'negative'. Credit rating agencies explained that these resul
- Company
- 'Ebglyss' can be prescribed at general hospitals
- by Eo, Yun-Ho Jul 9, 2025 06:10am
- 'Ebglyss,' a new drug for the treatment of atopic dermatitis, is now available for prescription at general hospitals. According to industry sources, Lily Korea's interleukin (IL)-13 inhibitor 'Ebglyss (lebrikizumab)' has passed the drug committees (DC) of tertiary general hospitals, including Seoul National University Hospital, Asan Medic
- Policy
- Daewoong’s generic version of Migbose approved in Korea
- by Lee, Hye-Kyung Jul 9, 2025 06:09am
- Daewoong Pharmaceutical has been approved to sell a generic version of the diabetes treatment Migbose Film-Coated Tablets (miglitol) in Korea. On the 7th, the Ministry of Food and Drug Safety approved Daewoong Pharmaceutical's Daewoong Miglitol Tab. (miglitol). Like the original Migbose, Daewoong Miglitol Tab is a film-coated tablet indica
- Company
- Adding amiloride effective in resistant hypertension
- by Son, Hyung Min Jul 9, 2025 06:08am
- A new treatment option has been proposed for patients with resistant hypertension that cannot be controlled even with the existing triple combination therapy for hypertension. A regimen combining an olmesartan-based triple combination therapy with the potassium-sparing diuretic ‘amiloride’ demonstrated similar blood pressure-lowering effec
- Opinion
- [Reporter's View] The revision of the Commercial Act
- by Kim, Jin-Gu Jul 9, 2025 06:08am
- The bill on revising the Commercial Act has passed the National Assembly. The bill expands the fiduciary duty of directors to include not only the “company” but also “shareholders,” mandates the introduction of electronic shareholder meetings for listed companies with assets of KRW 2 trillion or more, and changes the title of “outside d
- Policy
- Industry requests postponement of drug reimbursement reevals
- by Lee, Tak-Sun Jul 8, 2025 06:37am
- The pharmaceutical industry has expressed the need to postpone next year's drug reimbursement reevaluations to the government. The reason is that the reevaluation targets have not been decided by the second half of the year, leaving insufficient time for the target companies to prepare the necessary data. As a result, some are even sugges
- InterView
- V-olet challenges to become a blockbuster fat-destroying inj
- by Nho, Byung Chul Jul 8, 2025 06:36am
- Daewoong Pharmaceutical's V-olet Inj, a deoxycolic acid (DCA)-based fat-destroying injectable, is garnering attention as it implements an external expansion strategy to become a global blockbuster drug, following Nabota Inj. Launched in 2021, V-olet Inj is an injectable that demonstrates significant improvement in moderate-to-severe bulgi
- Policy
- Low-strength salt-modified Pristiq now available
- by Lee, Tak-Sun Jul 8, 2025 06:35am
- Companies with salt-modified formulations of the antidepressant Pristiq (desvenlafaxine succinate monohydrate) are strengthening their market competitiveness with a 25mg low-strength product that had not been available in the original or generic formulations. With price adjustments near due to the entry of generics, attention is focused o
- Company
- Novo Nordisk's injectables are in short supply
- by Nho, Byung Chul Jul 8, 2025 06:35am
- Novo Nordisk's diabetes insulin injections are experiencing a short-term shortage, causing supply difficulties in prescribing settings in Korea. The products with limited supply include NovoRapid Flexpen·Novomix Flexpen·Levemir Flexpen. Novo Nordisk sent a notice to distributors, pharmacies, hospitals, and clinics late last month, inf
- Product
- KPDS ‘Gov’t action needed to counter price hike pressure’
- by Jul 8, 2025 06:35am
- The Korean Pharmacists for Democratic Society (President: Kyung-Lim Jeon, KPDS) urged the government to take decisive action against Trump and multinational pharmaceutical companies' pressure to raise drug prices. In a statement released on the 4th, the KPDS stated: “Trump signed an executive order on May 12 demanding a reduction in drug
